XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
FDA Approval and Financial Highlights: Zevra's MIPLYFFA™ (arimoclomol) received FDA approval as the first treatment for Niemann-Pick disease Type C, contributing to XOMA Royalty's growing portfolio, which also includes a 50% interest in TWIST Bioscience's early-stage assets. XOMA reported $9.9 million in cash receipts for Q3 2024, totaling $42.3 million for the first nine months of the year.
Financial Performance and Losses: XOMA Royalty recorded total income of $7.2 million in Q3 2024, a significant increase from $0.8 million in the same quarter of 2023, but faced a net loss of $17.2 million due to a $14 million impairment charge related to its Agenus Royalty Purchase Agreement.
Trade with 70% Backtested Accuracy
Analyst Views on XOMAP
No data
About the author
XOMA Royalty Corporation's Preferred Stock (XOMAP) Price Target Raised by 11.43% to 68.83
Price Target Update: The average one-year price target for XOMA Royalty Corporation - Preferred Stock has been revised to $68.83 per share, reflecting an 11.43% increase from the previous estimate of $61.78.
Analyst Range: Current analyst targets for the stock range from a low of $47.55 to a high of $106.56, indicating a potential increase of 159.12% from the last reported closing price of $26.56.
Fund Sentiment: There are currently 3 funds reporting positions in XOMA Royalty Corporation, a decrease of 25% from the previous quarter, with total shares owned by institutions down by 25.27% to 18,000 shares.
Shareholder Stability: Key shareholders, including Gabelli Global Small & Mid Cap Value Trust, Gabelli Healthcare & Wellnessrx Trust, and Gabelli Dividend & Income Trust, have maintained their shareholdings without any changes in the last quarter.
XOMA Royalty Announces Financial Results for Q3 and Year-to-Date 2025, Along with Recent Business Milestones
Business Development: XOMA Royalty has secured royalty interests in two partnered assets through its acquisition of LAVA Therapeutics and completed acquisitions of Turnstone Biologics and HilleVax, while also acting as a structuring agent for XenoTherapeutics' acquisition of ESSA Pharma.
Pipeline Advancements: Key developments include Zevra Therapeutics' submission of a Marketing Authorization Application for arimoclomol, Rezolute Bio's expected topline data announcement in December for its Phase 3 trial, and Gossamer Bio's anticipated results from its Phase 3 trial of seralutunib in February 2026.
Financial Performance: In the first nine months of 2025, XOMA Royalty reported $43.9 million in cash receipts, with a net income of $25.6 million, a significant improvement from net losses in the same period of 2024.
Cash Position and Future Outlook: As of September 30, 2025, XOMA Royalty had $130.6 million in cash and cash equivalents, with plans to leverage its growing portfolio for future revenue generation while maintaining a healthy cash balance.
XOMA Royalty Prolongs Tender Offer to Purchase LAVA Therapeutics N.V.
Tender Offer Extension: XOMA Royalty Corporation has extended its tender offer for LAVA Therapeutics' shares until October 17, 2025, allowing shareholders to receive cash and a contingent value right based on future proceeds from LAVA's partnered and unpartnered assets.
Acquisition Process: The acquisition is expected to close in Q4 2025, contingent on certain conditions including the tender of at least 80% of LAVA's shares and the adoption of specific resolutions by LAVA's shareholders.
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
Acquisition Announcement: XOMA Royalty Corporation has entered into a definitive share purchase agreement to acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, along with a contingent value right representing 75% of the net proceeds from LAVA's partnered assets.
Transaction Details: The tender offer is expected to commence by August 15, 2025, with the closing anticipated in the fourth quarter of 2025, subject to conditions including shareholder approval and minimum share tendering requirements.
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
Merger Announcement: HilleVax, Inc. has entered into a definitive merger agreement with XOMA Royalty Corporation, where XOMA will acquire all outstanding shares of HilleVax for $1.95 per share in cash and contingent value rights, with the acquisition expected to close in September 2025.
Support and Conditions: The merger has received unanimous approval from HilleVax's Board of Directors, and certain stockholders representing approximately 22.9% of HilleVax common stock have agreed to support the transaction by tendering their shares, subject to customary closing conditions.
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
Merger Announcement: XOMA Royalty Corporation has entered into a definitive merger agreement to acquire Turnstone Biologics Corp. for $0.34 in cash per share, along with a non-transferable contingent value right (CVR), with the transaction expected to close in August 2025.
Board Approval and Support: The Turnstone Board of Directors unanimously approved the acquisition, and approximately 25.2% of Turnstone stockholders have signed agreements to support the merger by tendering their shares.
XOMA Royalty Corporation's Preferred Stock (XOMAP) Price Target Raised by 11.43% to 68.83
Price Target Update: The average one-year price target for XOMA Royalty Corporation - Preferred Stock has been revised to $68.83 per share, reflecting an 11.43% increase from the previous estimate of $61.78.
Analyst Range: Current analyst targets for the stock range from a low of $47.55 to a high of $106.56, indicating a potential increase of 159.12% from the last reported closing price of $26.56.
Fund Sentiment: There are currently 3 funds reporting positions in XOMA Royalty Corporation, a decrease of 25% from the previous quarter, with total shares owned by institutions down by 25.27% to 18,000 shares.
Shareholder Stability: Key shareholders, including Gabelli Global Small & Mid Cap Value Trust, Gabelli Healthcare & Wellnessrx Trust, and Gabelli Dividend & Income Trust, have maintained their shareholdings without any changes in the last quarter.
XOMA Royalty Announces Financial Results for Q3 and Year-to-Date 2025, Along with Recent Business Milestones
Business Development: XOMA Royalty has secured royalty interests in two partnered assets through its acquisition of LAVA Therapeutics and completed acquisitions of Turnstone Biologics and HilleVax, while also acting as a structuring agent for XenoTherapeutics' acquisition of ESSA Pharma.
Pipeline Advancements: Key developments include Zevra Therapeutics' submission of a Marketing Authorization Application for arimoclomol, Rezolute Bio's expected topline data announcement in December for its Phase 3 trial, and Gossamer Bio's anticipated results from its Phase 3 trial of seralutunib in February 2026.
Financial Performance: In the first nine months of 2025, XOMA Royalty reported $43.9 million in cash receipts, with a net income of $25.6 million, a significant improvement from net losses in the same period of 2024.
Cash Position and Future Outlook: As of September 30, 2025, XOMA Royalty had $130.6 million in cash and cash equivalents, with plans to leverage its growing portfolio for future revenue generation while maintaining a healthy cash balance.
XOMA Royalty Prolongs Tender Offer to Purchase LAVA Therapeutics N.V.
Tender Offer Extension: XOMA Royalty Corporation has extended its tender offer for LAVA Therapeutics' shares until October 17, 2025, allowing shareholders to receive cash and a contingent value right based on future proceeds from LAVA's partnered and unpartnered assets.
Acquisition Process: The acquisition is expected to close in Q4 2025, contingent on certain conditions including the tender of at least 80% of LAVA's shares and the adoption of specific resolutions by LAVA's shareholders.
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
Acquisition Announcement: XOMA Royalty Corporation has entered into a definitive share purchase agreement to acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, along with a contingent value right representing 75% of the net proceeds from LAVA's partnered assets.
Transaction Details: The tender offer is expected to commence by August 15, 2025, with the closing anticipated in the fourth quarter of 2025, subject to conditions including shareholder approval and minimum share tendering requirements.
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
Merger Announcement: HilleVax, Inc. has entered into a definitive merger agreement with XOMA Royalty Corporation, where XOMA will acquire all outstanding shares of HilleVax for $1.95 per share in cash and contingent value rights, with the acquisition expected to close in September 2025.
Support and Conditions: The merger has received unanimous approval from HilleVax's Board of Directors, and certain stockholders representing approximately 22.9% of HilleVax common stock have agreed to support the transaction by tendering their shares, subject to customary closing conditions.
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
Merger Announcement: XOMA Royalty Corporation has entered into a definitive merger agreement to acquire Turnstone Biologics Corp. for $0.34 in cash per share, along with a non-transferable contingent value right (CVR), with the transaction expected to close in August 2025.
Board Approval and Support: The Turnstone Board of Directors unanimously approved the acquisition, and approximately 25.2% of Turnstone stockholders have signed agreements to support the merger by tendering their shares.
